Axsome Therapeutics Inc AXSM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 52.38M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.25
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 925
- Website
- https://www.axsome.com
Valuation
|
Metric
|
AXSM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 98.13 |
Price/Sales | 10.25 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AXSM
|
|---|---|
Quick Ratio | 1.30 |
Current Ratio | 1.43 |
Interest Coverage | −37.09 |
Quick Ratio
AXSM
Profitability
|
Metric
|
AXSM
|
|---|---|
Return on Assets (Normalized) | −16.26% |
Return on Equity (Normalized) | −151.39% |
Return on Invested Capital (Normalized) | −37.03% |
Return on Assets
AXSM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#B%$QC$ | LOCK|T!?^K | $133B | |||
| Moderna Inc
MRNA
| LOCK|d^!!Zwn | LOCK|QK | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&^V!FgS | LOCK|<%yg | $83B | |||
| argenx SE ADR
ARGX
| LOCK|xM!zB^ | LOCK|t!> | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|FxZJy$k | LOCK|MqD | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#&WjW@x | LOCK|$X&> | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|C?kqhq?^ | LOCK|YWC!s | $28B | |||
| Incyte Corp
INCY
| LOCK|P>D?df# | LOCK|%#G | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|w>#n@?k | LOCK|Ks | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|z<KwXCX | LOCK|^@ | $14B |
United States